Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indaptus Therapeutics, Inc. (INDP : NSDQ)

• Company Description    Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec Parent Inc., is based in NEW YORK. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $12.34 Daily Weekly Monthly 20 Day Moving Average: 697,688 shares Shares Outstanding: 0.57 (millions) Market Capitalization: $7.06 (millions) Beta: 1.35 52 Week High: $66.64 52 Week Low: $7.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 29.91% 25.05% 12 Week -8.22% -22.80% Year To Date -47.69% -51.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 COLUMBUS CIRCLE 15TH FLOOR - NEW YORK,NY 10019 USA ph: 646-427-2727 fax: 972-2586-9176 investors@indaptusrx.com https://indaptusrx.com

• General Corporate Information    Officers Jeffrey A. Meckler - Chief Executive Officer and Director Roger J. Pomerantz - Chairman of the Board of Directors Nir Sassi - Chief Financial Officer Michael J. Newman - Director Hila Karah - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45339J204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 0.57 Most Recent Split Date: 6.00 (0.04:1) Beta: 1.35 Market Capitalization: $7.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 28.89% vs. Previous Quarter: 15.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -333.02 12/31/24 - -235.87 ROA 06/30/25 - - 03/31/25 - -216.36 12/31/24 - -173.41 Current Ratio 06/30/25 - - 03/31/25 - 1.90 12/31/24 - 1.95 Quick Ratio 06/30/25 - - 03/31/25 - 1.90 12/31/24 - 1.95 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 4.89 12/31/24 - 10.84 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©